Navigation Links
Angelini Labopharm Confirms Appointment of Mary Anne Heino as President
Date:1/25/2011

PRINCETON, N.J., Jan. 25, 2011 /PRNewswire/ -- Angelini Labopharm, LLC, today confirmed Mary Anne Heino's appointment as President of the Company.  Formerly Senior Vice President, Sales and Marketing for Labopharm Inc. and President of the company's wholly owned subsidiary, Labopharm USA, Inc., Ms. Heino's primary focus will be to leverage the Angelini Labopharm joint venture for the commercialization of OLEPTRO™, as well as to explore opportunities for line-extensions and the introduction of other products to the U.S. market through the joint venture.

The Angelini Labopharm joint venture was formed in 2010 for the U.S. commercialization of OLEPTRO™, a novel, once-daily formulation of the antidepressant trazodone hydrochloride approved by the U.S. Food and Drug Administration (FDA) for the symptomatic relief of major depressive disorder (MDD) in adults.  

"As acting President of Angelini Labopharm, Mary Anne played an instrumental role in the commercial preparation for the U.S. launch of OLEPTRO™ last August and we look forward to her continued contributions toward the build out of the joint venture," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc.

"Mary Anne's proven leadership in the management of the Angelini Labopharm joint venture gives us great confidence in the successful growth and performance of this partnership as we focus on expansion efforts in the United States," said Gianluigi Frozzi, Chief Executive Officer of the Pharmaceutical Division, Gruppo Angelini.

Prior to joining Labopharm in February 2007, Ms. Heino held executive positions with Centocor, Inc., a subsidiary of Johnson & Johnson, including Vice President of Strategic Planning and Competitive Intelligence and Vice President of Sales, in which she directed a sales team that generated revenue of more than $2 billion annually. Prior to Centocor, Ms. Heino held a series of increasingly senior sa
'/>"/>

SOURCE Angelini Labopharm, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Labopharm files New Drug Submission with Health Canada for novel antidepressant
2. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
3. IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
4. Study Confirms That New Protocol Shortens the Time It Takes to Open Blocked Arteries for Heart Attack Patients
5. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
6. FDA Confirms Seizure of Eyelash Product Was Not Prompted by Reports of Adverse Effects
7. Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer
8. New Study Confirms Dose-Accuracy of SoloSTAR(R) Prefilled Insulin Pen
9. AviaraDx Confirms That Combination of Two Molecular Biomarkers Improves Prediction of Disease Recurrence in Early Stage Breast Cancer Patients
10. Study Confirms That Avastin Significantly Increases Chance of Living Without Disease Progression in Metastatic Breast Cancer
11. University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 23, 2014 Research and Markets ... Gloves (Exam and Surgical) Markets Worldwide 2014" report ... The purpose of this report is ... Medical (Exam and Surgical) Gloves. The report discusses key ... products. Topics covered include product definitions, strategies, ...
(Date:7/23/2014)... , July 23, 2014  Lightlake Therapeutics Inc. ... treatments based on its expertise in opioid antagonists, ... new drug application ("IND") with respect to its ... announced today that it has received an additional ... ("NIDA"), part of the National Institutes of Health ...
(Date:7/23/2014)... , July 23, 2014 This September leading ... Las Vegas for DOCtalk ... educator, author, forward thinker and private practitioner Dr. ... together to candidly discuss clinical and practice management efficiency ... is a unique opportunity to welcome fresh thinking and ...
Breaking Medicine Technology:Disposable Medical Gloves (Exam and Surgical) Markets Worldwide 2014 2Disposable Medical Gloves (Exam and Surgical) Markets Worldwide 2014 3Disposable Medical Gloves (Exam and Surgical) Markets Worldwide 2014 4Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 2Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 32014 DOCtalk Registration Now Open 22014 DOCtalk Registration Now Open 3
... Therapeutics,today announced the presentation of data on the ... American Transplant,meeting to be held in San Francisco, ... with scientists at the University of,Western Ontario., "These ... extend graft,survival in transplantation, and that it can ...
... at Least 75 Percent Improvement in Psoriasis,Signs and ... Dosing Groups, More,Than Half Achieved 90 Percent Improvement, ... New,Phase II study results show Abbott's investigational treatment,ABT-874, ... treated. At 12 weeks, nine out of 10 ...
Cached Medicine Technology:Argos Therapeutics Presents Immunosuppression Data for Soluble CD83,at the American Society of Transplantation Congress 2007 2Abbott's Investigational Treatment ABT-874 Shows Positive Results,in Phase II Psoriasis Study 2Abbott's Investigational Treatment ABT-874 Shows Positive Results,in Phase II Psoriasis Study 3Abbott's Investigational Treatment ABT-874 Shows Positive Results,in Phase II Psoriasis Study 4
(Date:7/23/2014)... 23, 2014 (HealthDay News) -- Regularly checking the pulse ... researchers report. "Screening pulse is the method of ... age 65 who have never had a stroke. Our ... and easy way to identify people who might need ... study author Dr. Bernd Kallmunzer, of Erlangen University in ...
(Date:7/23/2014)... National Institute of Biomedical Imaging and Bioengineering will host ... July 30, 2014 on the NIH campus. There will ... a wide breadth of NIBIB-funded research. , ... Engineering Microbial Rhodopsins as Optical Voltage Sensor, Quyen ... Probes for Nerve Imaging during Surgery, ...
(Date:7/23/2014)... Los Angeles, CA (PRWEB) July 23, 2014 ... physician practices delivering Enhanced External Counterpulsation (EECP), ... patient who receives EECP therapy at the health center. ... and ischemic heart disease. Since receiving ongoing EECP therapy ... , When Sara Soulati, CEO of Global Cardio ...
(Date:7/23/2014)... RIVERSIDE, Calif. Fragile X syndrome ( FXS ) ... behaviors, and other behaviors on the autistic spectrum, as ... inherited cause of mental impairment and the most common ... University of California, Riverside have published a study ... behaviors in FXS. Appearing online today (July 23) in ...
(Date:7/23/2014)... PA (PRWEB) July 23, 2014 Four ... have been lauded in the latest ranking of the ... Report . Released online today and slated for ... Guide recognizes Allegheny General Hospital (AGH), Forbes Hospital, Saint ... medical centers across multiple clinical specialties. , ...
Breaking Medicine News(10 mins):Health News:Routine Pulse Check May Prevent Second Stroke, Study Says 2Health News:Global Cardio Care Celebrates EECP Patient’s 100th Birthday 2Health News:Study links enzyme to autistic behaviors 2Health News:Study links enzyme to autistic behaviors 3Health News:Four Allegheny Health Network Hospitals Named High Performers by U.S. News 2Health News:Four Allegheny Health Network Hospitals Named High Performers by U.S. News 3
... Va., April 16 Since the inaugural National ... than one million advance directive forms have been ... Organization,s Caring Connections program. Today, the 2nd Annual ... age or current health are reminded of the ...
... #H1/F38 - Varian Medical Systems, Inc. (NYSE: VAR ... digital X-ray image detectors will exhibit its line of PaxScan ... the China International Medical Equipment Fair (CMEF) meeting in Shenzhen, ... showcase its full range of X-ray tubes for fluoroscopy, angiography, ...
... For His Discoveries About Attention And Memory, ... 16 NeuroFocus, the world leader in ... application of brainwave-based measurements for market research ... named a Partner in the company,s Consulting ...
... BLOOMINGTON, Minn., April 16 Pearson VUE, the ... it has signed an exclusive agreement with the ... be the exclusive test delivery provider of the ... CCMA examinations are delivered throughout the secure Pearson ...
... Chance to Look Like a Star with Milk on ... Only at bodybymilk.comWASHINGTON , April 16 Warding ... superheroes like Wolverine need a little help. (Photo: ... to rebuild his body far faster than any ordinary ...
... the disease, not the symptoms)HUDSON, Fla., April 16 Workforce Prescriptions ("WRX") announced on ... their unique labor waste derived from 7 sources: , , ... Agency utilization , Other "Premium Pay" ... avoidable days , Process labor waste , ...
Cached Medicine News:Health News:2nd Annual National Healthcare Decisions Day Builds on Growing Awareness of Advance Care Planning 2Health News:Varian Medical Systems to Exhibit the Latest X-Ray Image Detectors, and X-Ray Tubes at the CMEF Show in Shenzhen, China 2Health News:NeuroFocus Appoints Dr. Michael Smith as Partner in Consulting Practice 2Health News:California Certifying Board for Medical Assistants Signs Exclusive Contract with Pearson VUE 2Health News:X-Men's Wolverine Depends on Milk as His X-factor 2Health News:WRX Launches Hospital Labor Waste Calculator 2Health News:WRX Launches Hospital Labor Waste Calculator 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: